Expand all sections

Recombinant zoster vaccin

Shingrix

Extended indication Preventie van gordelroos bij personen van 50 jaar en ouder.
Therapeutic value No judgement
Total cost 2,010,367,200.00

Product

Active substance Recombinant zoster vaccin
Domain Infectious diseases
Main indication Viral infections other
Extended indication Preventie van gordelroos bij personen van 50 jaar en ouder.
Proprietary name Shingrix
Manufacturer GSK
Route of administration Intramuscular
Therapeutical formulation Injection
Additional remarks Dit is een recombinant zoster vaccin (i.t.t. Zostavax wat een levend verzwakt varicella-zostervirus is).

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
Submission date January 2017
Expected Registration February 2018
Orphan drug No

Therapeutic value

Current treatment options Zostavax
Therapeutic value No judgement
Duration of treatment Average 6 month / months
Dosage per administration 50 ug
Additional remarks Toedieningsfrequentie: eenmalig 2 injecties op t=0 en op t=2-6 maanden

Expected patient volume per year

Patient volume

< 6,701,224

Market share is generally not included unless otherwise stated.
References CBS
Additional remarks 6,7 mln. Inwoners van 50+, betreft het maximale volume.

Expected cost per patient per year

Cost 300.00
References Medicijnkosten.nl
Additional remarks Zostavax kost €144,54 per injectie (19400PU FL).

Potential total cost per year

Total cost

2,010,367,200.00

This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.